Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,562
  • Shares Outstanding, K 20,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,420 K
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.42
Trade TARA with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -20.12%)
  • Historical Volatility 50.24%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 473.68% on 11/30/23
  • IV Low 0.00% on 09/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 676
  • Open Int (30-Day) 572

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.52
  • Prior Year -0.87
  • Growth Rate Est. (year over year) +42.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +17.26%
on 09/11/24
2.3000 -14.35%
on 08/20/24
-0.1600 (-7.51%)
since 08/19/24
3-Month
1.6800 +17.26%
on 09/11/24
2.6500 -25.66%
on 07/11/24
-0.3700 (-15.81%)
since 06/18/24
52-Week
1.0400 +89.42%
on 11/22/23
5.2400 -62.40%
on 04/05/24
+0.2400 (+13.87%)
since 09/19/23

Most Recent Stories

More News
Veeva: Fiscal Q2 Earnings Snapshot

Veeva: Fiscal Q2 Earnings Snapshot

TARA : 1.9700 (+2.60%)
Protara Therapeutics: Q2 Earnings Snapshot

Protara Therapeutics: Q2 Earnings Snapshot

TARA : 1.9700 (+2.60%)
2 Stocks Under $10 Wall Street Says Are 'Strong Buys'

You can spend less and earn significant returns with these two cheap stocks.

TARA : 1.9700 (+2.60%)
$SPX : 5,713.64 (+1.70%)
OPT : 3.86 (+10.24%)
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents...

TARA : 1.9700 (+2.60%)
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 1.9700 (+2.60%)
Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash...

TARA : 1.9700 (+2.60%)
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 1.9700 (+2.60%)
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021...

TARA : 1.9700 (+2.60%)
Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 1.9700 (+2.60%)
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 1.9700 (+2.60%)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 2.0800
2nd Resistance Point 2.0500
1st Resistance Point 2.0100
Last Price 1.9700
1st Support Level 1.9400
2nd Support Level 1.9100
3rd Support Level 1.8700

See More

52-Week High 5.2400
Fibonacci 61.8% 3.6356
Fibonacci 50% 3.1400
Fibonacci 38.2% 2.6444
Last Price 1.9700
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar